繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
立即開戶
牛牛AI助理已提取核心訊息
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share for the quarter ended July 31, 2024. However, the company has disclosed its stock-based compensation expenses, which decreased year-on-year from $124,646 in 2023 to $54,554 in 2024. The company also reported a cumulative net operating loss for federal income tax purposes of approximately $56 million as of July 31, 2024, an increase from $54 million at the end of the previous fiscal year. Heart Test Laboratories has a long-term operating lease for its facilities, with rent expense for the quarter amounting to approximately $37,000. In terms of business development, the company has entered into collaboration agreements with Rutgers and Mount Sinai...Show More
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share for the quarter ended July 31, 2024. However, the company has disclosed its stock-based compensation expenses, which decreased year-on-year from $124,646 in 2023 to $54,554 in 2024. The company also reported a cumulative net operating loss for federal income tax purposes of approximately $56 million as of July 31, 2024, an increase from $54 million at the end of the previous fiscal year. Heart Test Laboratories has a long-term operating lease for its facilities, with rent expense for the quarter amounting to approximately $37,000. In terms of business development, the company has entered into collaboration agreements with Rutgers and Mount Sinai to develop AI-ECG algorithms, which are expected to enhance product development and expand clinical value. The company's future plans include seeking FDA clearances for its AI-ECG solutions and MyoVista wavECG device, with a 510(k) FDA submission targeted for the first quarter of 2025. Additionally, the company aims to submit its MyoVista Insights Cloud Platform and low ejection fraction algorithm for FDA review in mid-2025.
醫療技術公司心臟檢測實驗室並未提供截至2024年7月31日的財務績效指標,例如營業收入、營業利潤、淨利潤或每股攤薄收益。然而,該公司披露了其股票補償費用,2024年的費用從2023年的124,646美元下降到54,554美元。該公司還披露,截至2024年7月31日,其聯邦所得稅目的的累積淨營業虧損約爲5600萬美元,較上一財年末的5400萬美元增加。心臟檢測實驗室長期租用了其設施,本季度租金支出約爲37,000美元。在業務發展方面,該公司已與拉特格斯大學和西奈山合作,開發AI-ECG算法,預計能夠增強產品開發和擴大臨床價值。該公司未來的計劃包括尋求FDA對其AI-ECG解決方案和MyoVista wavECG設備的許可,並計劃在2025年第一季度提交510(k) FDA申請。此外,該公司還計劃在2025年中期向FDA提交MyoVista Insights雲平台和低射血分數算法進行審查。
醫療技術公司心臟檢測實驗室並未提供截至2024年7月31日的財務績效指標,例如營業收入、營業利潤、淨利潤或每股攤薄收益。然而,該公司披露了其股票補償費用,2024年的費用從2023年的124,646美元下降到54,554美元。該公司還披露,截至2024年7月31日,其聯邦所得稅目的的累積淨營業虧損約爲5600萬美元,較上一財年末的5400萬美元增加。心臟檢測實驗室長期租用了其設施,本季度租金支出約爲37,000美元。在業務發展方面,該公司已與拉特格斯大學和西奈山合作,開發AI-ECG算法,預計能夠增強產品開發和擴大臨床價值。該公司未來的計劃包括尋求FDA對其AI-ECG解決方案和MyoVista wavECG設備的許可,並計劃在2025年第一季度提交510(k) FDA申請。此外,該公司還計劃在2025年中期向FDA提交MyoVista Insights雲平台和低射血分數算法進行審查。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間